Expression and DNA methylation status of microRNA-375 in patients with type 2 diabetes mellitus

Sun,Kan; Chang,Xiangyun; Yin,Liang; Li,Jun; Zhou,Ting; Zhang,Chen; Chen,Xuan

doi:10.3892/mmr.2013.1872

Expression and DNA methylation status of microRNA-375 in patients with type 2 diabetes mellitus

Authors:
- Kan Sun
- Xiangyun Chang
- Liang Yin
- Jun Li
- Ting Zhou
- Chen Zhang
- Xuan Chen
View Affiliations

Affiliations: Department of Endocrinology and Metabolism, First Affiliated Hospital, Shihezi University School of Medicine, Shihezi, Xinjiang 832002, P.R. China, The Central Laboratory, First Affiliated Hospital, Shihezi University School of Medicine, Shihezi, Xinjiang 832002, P.R. China
Published online on: December 18, 2013 https://doi.org/10.3892/mmr.2013.1872
Pages: 967-972

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Recent studies have shown that DNA methylation in the promoter of microRNA-375 (miR-375) downregulates its expression during tumorigenesis. However, it is not known if CpG methylation of the miR-375 promoter also has a role in the pathogenesis of type 2 diabetes mellitus (T2DM). In this study, the expression level and CpG methylation status of miR-375 in patients with T2DM were analyzed. Plasma samples from 100 patients with T2DM and 100 healthy controls with normal glucose tolerance (NGT) were collected. The plasma levels of miR-375 were examined using quantitative polymerase chain reaction (qPCR) and the methylation status of 17 CpG sites in the promoter of the miR-375 were determined using MassARRAY spectrometry. The plasma levels of miR-375 were found to be upregulated in patients with T2DM compared with controls with NGT (P<0.05). Overall, the methylation levels of the miR-375 promoter in patients with T2DM were not significantly different compared with controls with NGT; however, further studies revealed that four of the eight analyzed individual CpG units within the amplicon were significantly hypomethylated in T2DM samples compared with the NGT samples. This study demonstrated for the first time, to the best of our knowledge, that miR-375 is overexpressed in plasma in patients with T2DM, and this may be used as a novel biomarker to distinguish between patients with T2DM and healthy individuals. It was also demonstrated in this study that the miR-375 promoter is hypomethylated, in patients with T2DM, which may regulate the expression of miR-375 and contribute to the pathogenesis of T2DM.

View Figures

View References

1	Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA and Butler PC: Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 52:102–110. 2003. View Article : Google Scholar : PubMed/NCBI
2	Guillausseau PJ, Meas T, Virally M, Laloi-Michelin M, Médeau V and Kevorkian JP: Abnormalities in insulin secretion in type 2 diabetes mellitus. Diabetes Metab. 34(Suppl 2): S43–S48. 2008. View Article : Google Scholar : PubMed/NCBI
3	Ambros V: The functions of animal microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
4	Bartel DP: MicroRNAs: target recognition and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
5	Uhlmann S, Zhang JD, Schwäger A, Mannsperger H, Riazalhosseini Y, Burmester S, et al: miR-200bc/429 cluster targets PLCgamma1 and differentially regulates proliferation and EGF-driven invasion than miR-200a/141 in breast cancer. Oncogene. 29:4297–4306. 2010. View Article : Google Scholar : PubMed/NCBI
6	Chang TC and Mendell JT: microRNAs in vertebrate physiology and human disease. Annu Rev Genomics Hum Genet. 8:215–239. 2007. View Article : Google Scholar : PubMed/NCBI
7	Poy MN, Eliasson L, Krutzfeldt J, Kuwajima S, Ma X, Macdonald PE, et al: A pancreatic islet-specific microRNA regulates insulin secretion. Nature. 432:226–230. 2004. View Article : Google Scholar : PubMed/NCBI
8	Poy MN, Hausser J, Trajkovski M, Braun M, Collins S, Rorsman P, et al: miR-375 maintains normal pancreatic alpha- and beta-cell mass. Proc Natl Acad Sci USA. 106:5813–5818. 2009. View Article : Google Scholar : PubMed/NCBI
9	Baroukh N, Ravier MA, Loder MK, Hill EV, Bounacer A, Scharfmann R, et al: MicroRNA-124a regulates Foxa2 expression and intracellular signaling in pancreatic beta-cell lines. J Biol Chem. 282:19575–19588. 2007. View Article : Google Scholar : PubMed/NCBI
10	Plaisance V, Abderrahmani A, Perret-Menoud V, Jacquemin P, Lemaigre F and Regazzi R: MicroRNA-9 controls the expression of Granuphilin/Slp4 and the secretory response of insulin-producing cells. J Biol Chem. 281:26932–26942. 2006. View Article : Google Scholar : PubMed/NCBI
11	Zhao H, Guan J, Lee HM, Sui Y, He L, Siu JJ, et al: Up-regulated pancreatic tissue microRNA-375 associates with human type 2 diabetes through beta-cell deficit and islet amyloid deposition. Pancreas. 39:843–846. 2010. View Article : Google Scholar : PubMed/NCBI
12	Gardner RJ, Mackay DJ, Mungall AJ, Polychronakos C, Siebert R, Shield JP, et al: An imprinted locus associated with transient neonatal diabetes mellitus. Hum Mol Genet. 9:589–596. 2000. View Article : Google Scholar : PubMed/NCBI
13	Ling C, Del Guerra S, Lupi R, Rönn T, Granhall C, Luthman H, et al: Epigenetic regulation of PPARGC1A in human type 2 diabetic islets and effect on insulin secretion. Diabetologia. 51:615–622. 2008. View Article : Google Scholar : PubMed/NCBI
14	de Souza Rocha Simonini P, Breiling A, Gupta N, Malekpour M, Youns M, Omranipour R, et al: Epigenetically deregulated microRNA-375 is involved in a positive feedback loop with estrogen receptor alpha in breast cancer cells. Cancer Res. 70:9175–9184. 2010.PubMed/NCBI
15	Tsukamoto Y, Nakada C, Noguchi T, Tanigawa M, Nguyen LT, Uchida T, et al: MicroRNA-375 is downregulated in gastric carcinomas and regulates cell survival by targeting PDK1 and 14–3–3zeta. Cancer Res. 70:2339–2349. 2010.PubMed/NCBI
16	Kong KL, Kwong DL, Chan TH, Law SY, Chen L, Li Y, et al: MicroRNA-375 inhibits tumour growth and metastasis in oesophageal squamous cell carcinoma through repressing insulin-like growth factor 1 receptor. Gut. 61:33–42. 2012. View Article : Google Scholar : PubMed/NCBI
17	Yang YN, Xie X, Ma YT, Li XM, Fu ZY, Ma X, et al: Type 2 diabetes in Xinjiang Uygur Autonomous Region, China. PLoS One. 7:e352702012. View Article : Google Scholar : PubMed/NCBI
18	Lin HJ, Zuo T, Lin CH, Kuo CT, Liyanarachchi S, Sun S, et al: Breast cancer-associated fibroblasts confer AKT1-mediated epigenetic silencing of cystatin M in epithelial cells. Cancer Res. 68:10257–10266. 2008. View Article : Google Scholar : PubMed/NCBI
19	Szczyrba J, Nolte E, Wach S, Kremmer E, Stöhr R, Hartmann A, et al: Downregulation of Sec23A protein by miRNA-375 in prostate carcinoma. Mol Cancer Res. 9:791–800. 2011. View Article : Google Scholar : PubMed/NCBI
20	Ding L, Xu Y, Zhang W, Deng Y, Si M, Du Y, Yao H, et al: MiR-375 frequently downregulated in gastric cancer inhibits cell proliferation by targeting JAK2. Cell Res. 20:784–793. 2010. View Article : Google Scholar : PubMed/NCBI
21	Li Y, Xu X, Liang Y, Liu S, Xiao H, Li F, et al: miR-375 enhances palmitate-induced lipoapoptosis in insulin-secreting NIT-1 cells by repressing myotrophin (V1) protein expression. Int J Clin Exp Pathol. 3:254–264. 2010.PubMed/NCBI
22	Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 105:10513–10518. 2008. View Article : Google Scholar : PubMed/NCBI
23	Weber B, Stresemann C, Brueckner B and Lyko F: Methylation of human microRNA genes in normal and neoplastic cells. Cell Cycle. 6:1001–1005. 2007. View Article : Google Scholar : PubMed/NCBI